Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
1 "Hepatic toxicity"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Article
Treatment Outcome after Fractionated Conformal Radiotherapy for Hepatocellular Carcinoma in Patients with Child-Pugh Classification B in Korea (KROG 16-05)
Sun Hyun Bae, Hee Chul Park, Won Sup Yoon, Sang Min Yoon, In-Hye Jung, Ik Jae Lee, Jun Won Kim, Jinsil Seong, Tae Hyun Kim, Taek-Keun Nam, Youngmin Choi, Sun Young Lee, Hong Seok Jang, Dong Soo Lee, Jin Hee Kim
Cancer Res Treat. 2019;51(4):1589-1599.   Published online April 10, 2019
DOI: https://doi.org/10.4143/crt.2018.687
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
There is limited data on radiotherapy (RT) for hepatocellular carcinoma (HCC) in patients with Child-Pugh classification B (CP-B). This study aimed to evaluate the treatment outcomes of fractionated conformal RT in HCC patients with CP-B.
Materials and Methods
We retrospectively reviewed the data of HCC patients with CP-B treated with RT between 2009 and 2014 at 13 institutions in Korea. HCC was diagnosed by the Korea guideline of 2009, and modern RT techniques were applied. Fraction size was ≤ 5 Gy and the biologically effective dose (BED) ≥ 40 Gy10 (α/β = 10 Gy). A total of 184 patients were included in this study.
Results
Initial CP score was seven in 62.0% of patients, eight in 31.0%, and nine in 7.0%. Portal vein tumor thrombosis was present in 66.3% of patients. The BED ranged from 40.4 to 89.6 Gy10 (median, 56.0 Gy10). After RT completion, 48.4% of patients underwent additional treatment. The median overall survival (OS) was 9.4 months. The local progression-free survival and OS rates at 1 year were 58.9% and 39.8%, respectively. In the multivariate analysis, non-classic radiation-induced liver disease (RILD) (p < 0.001) and additional treatment (p < 0.001) were the most significant prognostic factors of OS. Among 132 evaluable patients without progressive disease, 19.7% experienced non-classic RILD. Normal liver volume was the most predictive dosimetric parameter of non-classic RILD.
Conclusion
Fractionated conformal RT showed favorable OS with a moderate risk non-classic RILD. The individual radiotherapy for CP-B could be cautiously applied weighing the survival benefits and the RILD risks.

Citations

Citations to this article as recorded by  
  • Development and validation of a nomogram for radiation-induced hepatic toxicity after intensity modulated radiotherapy for hepatocellular carcinoma: a retrospective study
    Qiaoyuan Wu, Yudan Wang, Yuxin Wei, Zhengqiang Yang, Kai Chen, Jianxu Li, Liqing Li, Tingshi Su, Shixiong Liang
    Japanese Journal of Clinical Oncology.2024; 54(6): 699.     CrossRef
  • Managing hepatocellular carcinoma across the stages: efficacy and outcomes of stereotactic body radiotherapy
    Ahmed Allam Mohamed, Marie-Luise Berres, Philipp Bruners, Sven Arke Lang, Christian Trautwein, Georg Wiltberger, Alexandra Barabasch, Michael Eble
    Strahlentherapie und Onkologie.2024; 200(8): 715.     CrossRef
  • Clinical outcomes and safety of external beam radiotherapy with extensive intrahepatic targets for advanced hepatocellular carcinoma: A single institutional clinical experience
    Sunmin Park, Chai Hong Rim, Won Sup Yoon
    Saudi Journal of Gastroenterology.2024;[Epub]     CrossRef
  • Role of rapid arc-image-guided radiotherapy in hepatocellular carcinoma with portal vein tumor thrombosis: A study from tertiary care center in Punjab, India
    Manjinder Singh Sidhu, Ramandeep, Sandhya Sood, Ritu Aggarwal, Kulbir Singh, Divyanshi Sood
    Journal of Cancer Research and Therapeutics.2023; 19(3): 639.     CrossRef
  • Non-classic radiation-induced liver disease after intensity-modulated radiotherapy for Child–Pugh grade B patients with locally advanced hepatocellular carcinoma
    Jian-Xu Li, Rui-Jun Zhang, Mo-Qin Qiu, Liu-Ying Yan, Mei-Ling He, Mei-Ying Long, Jian-Hong Zhong, Hai-Yan Lu, Hong-Mei Zhou, Bang-De Xiang, Shi-Xiong Liang
    Radiation Oncology.2023;[Epub]     CrossRef
  • Long-term characterization of MRI-morphologic alterations after active motion-compensated liver SBRT: a multi-institutional pooled analysis
    Constantin Dreher, Gustavo R. Sarria, Georgia Miebach, Christel Weiss, Daniel Buergy, Paulina Wojtal, Anoshirwan A. Tavakoli, David Krug, Hans Oppitz, Frank A. Giordano, Marcus Both, Frank Lohr, Jürgen Dunst, Oliver Blanck, Judit Boda-Heggemann
    Acta Oncologica.2023; 62(3): 281.     CrossRef
  • Radiotherapy trend in elderly hepatocellular carcinoma: retrospective analysis of patients diagnosed between 2005 and 2017
    Bong Kyung Bae, Jeong Il Yu, Hee Chul Park, Myung Ji Goh, Yong-Han Paik
    Radiation Oncology Journal.2023; 41(2): 98.     CrossRef
  • Radiotherapy plus anti-PD1 versus radiotherapy for hepatic toxicity in patients with hepatocellular carcinoma
    Rui-Jun Zhang, Hong-Mei Zhou, Hai-Yan Lu, Hong-Ping Yu, Wei-Zhong Tang, Mo-Qin Qiu, Liu-Ying Yan, Mei-Ying Long, Ting-Shi Su, Bang-De Xiang, Mei-Ling He, Xiao-Ting Wang, Shi-Xiong Liang, Jian-Xu Li
    Radiation Oncology.2023;[Epub]     CrossRef
  • Low-dose radiotherapy combined with dual PD-L1 and VEGFA blockade elicits antitumor response in hepatocellular carcinoma mediated by activated intratumoral CD8+ exhausted-like T cells
    Siqi Li, Kun Li, Kang Wang, Haoyuan Yu, Xiangyang Wang, Mengchen Shi, Zhixing Liang, Zhou Yang, Yongwei Hu, Yang Li, Wei Liu, Hua Li, Shuqun Cheng, Linsen Ye, Yang Yang
    Nature Communications.2023;[Epub]     CrossRef
  • Stereotactic ablative radiotherapy for pulmonary oligometastases from primary hepatocellular carcinoma: a multicenter and retrospective analysis (KROG 17-08)
    In Young Jo, Hee Chul Park, Eun Seog Kim, Seung-Gu Yeo, Myungsoo Kim, Jinsil Seong, Jun Won Kim, Tae Hyun Kim, Won Sup Yoon, Bae Kwon Jeong, Sung Hwan Kim, Jong Hoon Lee
    Japanese Journal of Clinical Oncology.2022; 52(6): 616.     CrossRef
  • Efficacy and feasibility of surgery and external radiotherapy for hepatocellular carcinoma with portal invasion: A meta-analysis
    Han Ah Lee, Yeon Seok Seo, In-Soo Shin, Won Sup Yoon, Hye Yoon Lee, Chai Hong Rim
    International Journal of Surgery.2022; 104: 106753.     CrossRef
  • Trend Analysis and Prediction of Hepatobiliary Pancreatic Cancer Incidence and Mortality in Korea
    Hyeong Min Park, Young-Joo Won, Mee Joo Kang, Sang-Jae Park, Sun-Whe Kim, Kyu-Won Jung, Sung-Sik Han
    Journal of Korean Medical Science.2022;[Epub]     CrossRef
  • Radiofrequency ablation and stereotactic body radiotherapy for hepatocellular carcinoma: should they clash or reconcile?
    Chai Hong Rim, Hye Yoon Lee, Jung Sun Kim, Hakyoung Kim
    International Journal of Radiation Biology.2021; 97(2): 111.     CrossRef
  • Therapeutic Decision Making in Hepatocellular Carcinoma According to Age and Child–Pugh Class: A Nationwide Cohort Analysis in South Korea
    Sunmin Park, Chai Hong Rim, Young Kul Jung, Won Sup Yoon, Alessandro Granito
    Canadian Journal of Gastroenterology and Hepatology.2021; 2021: 1.     CrossRef
  • Benefits of Local Treatment Including External Radiotherapy for Hepatocellular Carcinoma with Portal Invasion
    Han Lee, Sunmin Park, Yeon Seo, Won Yoon, Chai Rim
    Biology.2021; 10(4): 326.     CrossRef
  • Phase I Radiation Dose-Escalation Study to Investigate the Dose-Limiting Toxicity of Concurrent Intra-Arterial Chemotherapy for Unresectable Hepatocellular Carcinoma
    Yeona Cho, Jun Won Kim, Ja Kyung Kim, Kwan Sik Lee, Jung Il Lee, Hyun Woong Lee, Kwang-Hun Lee, Seung-Moon Joo, Jin Hong Lim, Ik Jae Lee
    Cancers.2020; 12(6): 1612.     CrossRef
  • Do Biliary Complications after Proton Beam Therapy for Perihilar Hepatocellular Carcinoma Matter?
    Gyu Sang Yoo, Jeong Il Yu, Hee Chul Park, Dongho Hyun, Woo Kyoung Jeong, Ho Yeong Lim, Moon Seok Choi, Sang Yun Ha
    Cancers.2020; 12(9): 2395.     CrossRef
  • Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond
    Yun Hua Lee, David Tai, Connie Yip, Su Pin Choo, Valerie Chew
    Frontiers in Immunology.2020;[Epub]     CrossRef
  • 8,500 View
  • 236 Download
  • 19 Web of Science
  • 18 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP